// App-Quantinova.ai

4954 : Nuclear localized AR-V7 protein as a predictive biomarker for treatment selection in metastatic castration resistant prostate cancer (mCRPC)

Researchers

Presenter

  • Howard I. Scher

Principal Investigators

  • David Lu

  • Nicole A. Schreiber

  • Jessica Louw

  • Ryon P. Graf

  • Ann Johnson

  • Adam Jendrisak

  • Glenn Heller

  • Richard Bambury

  • Herbert A. Vargas Alverez

  • Brigit McLaughlin

  • Justin Wahl

  • Stephanie Greene

  • Martin Fleisher

  • Ryan Dittamore

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Epic Sciences, Inc., San Diego, CA

Locations

  • United States

Companies

  • EPIC SCIENCES, INC.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Androgen receptor variant 7

  • Circulating tumor cells

Drug/Treatment

  • taxane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved